ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 0.7 | 0.3 | 0.0 |
| Total income | 0.7 | 0.3 | 0.0 |
| Profit before exceptional items & tax | -0.1 | -0.1 | -0.0 |
| Profit before tax | -0.1 | -0.1 | -0.0 |
| Net profit | -0.1 | -0.1 | -0.0 |
| Operating margin | -14.3% | -33.3% | 0.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
BSE results filing, NSE: VINRKLB. Figures extracted from the filing.
Rekvina Laboratories Ltd: key numbers
- Share price
- ₹72.62
- Market cap
- ₹43.78 Cr
- Revenue (annual)
- ₹1.27 Cr
- Net profit (annual)
- ₹-0.25 Cr
- P/E (TTM)
- -122.0×Sector 43.7×
- Promoter holding
- 77.00%+35.70% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rekvina Laboratories Ltd
All →Rekvina Laboratories Financial Results
Rekvina Laboratories' board approved unaudited Q2 and half-year results to September 2026. It also appointed a Company Secretary effective 16 November 2026.
Rekvina Laboratories Q2 FY27 Results: Net Profit ₹0.1 Cr
Rekvina Laboratories Ltd reported revenue from operations of ₹3.6 Cr (+1700.0% YoY) and net profit of ₹0.1 Cr for Q2 FY27.
- Key figure
- Net profit ₹0.1 Cr
Rekvina Laboratories Board Meeting Date
Rekvina Laboratories has scheduled its Board meeting for November 13, 2026, to approve Q2 FY27 un-audited financial results. No material financial figures are disclosed at this stage.
Rekvina Laboratories Business Update
Subsidiary Radiant Parenterals will temporarily shut its manufacturing facility from October 28, 2026. The shutdown supports renovation and installation of an additional vial line.
Rekvina Laboratories Other Announcement
Rekvina Laboratories Limited submitted the certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Rekvina Laboratories Management Change
Rekvina Laboratories Limited has appointed Mr. Subrata Samanta as its new Chief Financial Officer and Key Managerial Personnel, effective October 7, 2026.